GHS-R1 Inhibitors
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
YIL 781 | 875258-85-8 | sc-361410 sc-361410A | 10 mg 50 mg | $179.00 $825.00 | ||
YIL 781 acts as a potent acid halide, characterized by its ability to engage in nucleophilic acyl substitution reactions. Its unique reactivity profile is attributed to the presence of highly polarized carbonyl groups, which enhance electrophilicity. This compound exhibits rapid reaction kinetics, allowing for efficient acylation of various nucleophiles. Additionally, YIL 781's steric properties influence selectivity, enabling tailored interactions with specific substrates in synthetic pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and metabolism. Inhibition of mTOR can indirectly affect GHS-R1 signaling, potentially inhibiting its role in energy homeostasis and growth hormone release. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 inhibits Wnt production, thereby modulating Wnt signaling pathways. This can indirectly inhibit GHS-R1, especially in pathways related to energy metabolism and appetite regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor affecting the MAPK/ERK pathway. By inhibiting this pathway, it might indirectly inhibit GHS-R1′s involvement in cellular signaling related to growth hormone regulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB, a transcription factor that can be activated downstream of GHS-R1 signaling. Inhibiting NF-κB might reduce the transcription of genes regulated in response to GHS-R1 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter the PI3K/Akt signaling pathway, potentially affecting GHS-R1-mediated signaling in energy metabolism and appetite regulation. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin activates AMPK, influencing cellular energy status. This activation can indirectly inhibit GHS-R1 signaling pathways involved in energy homeostasis. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib inhibits JAK, a kinase involved in cytokine signaling. Inhibition of JAK can indirectly influence GHS-R1-mediated signaling pathways in growth hormone regulation. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid influences gene expression and can lead to changes in cellular processes that might indirectly inhibit GHS-R1 activity, particularly in metabolic regulation. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Fludarabine inhibits STAT activation, a downstream component of GHS-R1 signaling. Inhibiting STAT may lead to reduced transcriptional activity following GHS-R1 activation. | ||||||